Oncolytics Biotech ($ONCY) Stock Hub: Oncolytics Aligns With the FDA on a Registrational Path for Pelareorep, and REO 033 Part A Data Decide When Part B Starts

01 Written FDA feedback of August 18, 2026 on a pivotal Part B of REO 033: what the company asked and what it reports

On August 18, 2026 Oncolytics reported that the FDA had provided written responses on the design of a potential pivotal Part B expansion of REO 033, its randomized study in second-line RAS-mutant MSS metastatic colorectal cancer. The company had submitted a Type D meeting request asking whether the ongoing Part A (n=60) could support a pivotal Part B and whether Part B could support accelerated approval on objective response rate and duration of response, with progression-free survival as the basis for full approval. In the company’s words the responses represent important alignment on the proposed design; the FDA suggested an End-of-Phase meeting to reach final agreement on key elements of the registration program, and Oncolytics elected to forgo its scheduled Type D meeting. Part B start-up activities are to begin as soon as positive interim Part A data are available. The FDA letter itself is not public, and written feedback is neither an approval nor a Special Protocol Assessment.

02 Nasdaq minimum-bid deficiency opens a separate compliance clock

Oncolytics received a Nasdaq notice after ONCY closed below $1.00 for 30 consecutive business days. The notice had no immediate effect on trading, but the company must regain compliance by January 19, 2027 or qualify for additional time; otherwise the shares could become subject to delisting proceedings.

03 FDA grants pelareorep Fast Track designation in second-line and later anal cancer

The FDA granted Fast Track designation to pelareorep in combination with a checkpoint inhibitor for patients with inoperable, locally recurrent or metastatic squamous cell carcinoma of the anal canal who progressed on, or were intolerant to, at least one prior systemic therapy. This is pelareorep’s third gastrointestinal-cancer Fast Track designation, after pancreatic cancer in 2022 and KRAS-mutant MSS metastatic colorectal cancer in February 2026.

The designation is supported by company-reported GOBLET data showing an objective response rate around 30%, median duration of response around 15.5 months and 12-month overall survival of 82%, compared by the company with historical benchmarks. These comparisons are encouraging but are not equivalent to evidence from a large randomized trial. Fast Track can increase FDA interaction and may permit rolling review of portions of a future application, but it is not an approval, a guarantee of Priority Review or proof that pelareorep is effective.

04 Executive summary: what matters most now

Oncolytics Biotech is no longer best understood as a broad oncolytic-virus research company running many proof-of-concept programs. The company has narrowed its operating strategy around pelareorep as a systemic immune-priming therapy for gastrointestinal tumors, with the clearest internally funded path now running through randomized colorectal cancer development and a planned pivotal anal cancer program. Pancreatic cancer remains scientifically and commercially important, but the company has stated that it does not expect to finance the proposed Phase 3 program on its own without a partner.

The clinical case rests on signals across several tumor types. Pelareorep has produced encouraging response, durability and survival signals in several difficult tumor types, including two randomized metastatic breast cancer studies and multiple pancreatic cancer datasets. In second-line KRAS-mutant MSS colorectal cancer, the company has reported a 33% objective response rate, 16.6-month median progression-free survival, 19.5-month median duration of response and 27-month median overall survival. In advanced anal cancer, company-reported response rates have clustered around 30%, including complete responses in heavily pretreated patients. These outcomes are the reason the FDA has now granted multiple Fast Track designations and engaged with Oncolytics on potential registration-directed designs.

The central limitation is equally important: the most valuation-sensitive colorectal and anal cancer signals were generated in small cohorts and were compared largely with historical benchmarks. Historical comparisons can be distorted by patient selection, treatment era, supportive care and many other variables. REO 033 is therefore the most important trial in the company’s history to date because it is designed to test whether the colorectal signal survives a prospective, randomized comparison against a contemporary control arm.

The constructive case

Pelareorep has shown a recurring biological and clinical pattern across tumors: immune activation, responses in cancers generally considered immunologically “cold,” and survival signals that have sometimes appeared larger than the response-rate difference alone. FDA engagement, three GI Fast Tracks, a manufacturing patent expected to protect the process into 2044 and a management team increasingly built around late-stage execution and transactions strengthen the strategic case.

The caution case

Oncolytics had only $4.12 million in cash at June 30, 2026, used $8.14 million in operating cash during Q2 and closed the quarter with a shareholders’ deficit of $6.17 million. The company has relied heavily on ATM issuance, its filings contain a going-concern warning, and shares outstanding expanded sharply from the end of 2024 through August 2026. Positive data can improve financing terms, but the clinical strategy remains dependent on additional capital, partnering or both.

Nasdaq compliance is now a live equity-risk variable

The July 24 Form 8-K disclosed that ONCY had failed the Nasdaq Capital Market’s $1.00 minimum-bid requirement after 30 consecutive business days below the threshold. Trading continues and the initial cure period runs through January 19, 2027, but the issue adds reverse-split, further financing and eventual delisting risk if compliance is not restored.

The decision hinge

The Stock Hub should not be read as a binary choice between “pelareorep works” and “pelareorep does not work.” The more useful questions are: Will randomized REO 033 reproduce a clinically meaningful separation? Will the FDA accept an efficient registrational expansion? Can the anal cancer protocol be activated without an uneconomic financing? Can management convert the pancreatic and breast evidence into non-dilutive partnering value? The answers to those questions will determine whether regulatory momentum becomes an approvable, financeable development plan.

05 Company overview: what Oncolytics is today

Oncolytics Biotech is a clinical-stage biotechnology company developing a single principal platform asset, pelareorep, formerly known as REOLYSIN. Pelareorep is a proprietary formulation of a naturally occurring double-stranded RNA reovirus designed for intravenous administration. Unlike locally injected oncolytic viruses, pelareorep is intended to reach tumors systemically, selectively replicate in permissive cancer cells and stimulate both innate and adaptive anti-tumor immune responses.

The company was founded in Alberta in 1998 and spent much of its history building clinical experience across solid tumors. Its corporate and development identity evolved from direct tumor lysis toward a broader immune-oncology thesis: pelareorep may act as an immune-priming backbone that alters the tumor microenvironment and increases the effectiveness of chemotherapy, checkpoint inhibitors and potentially targeted agents.

On March 31, 2026, Oncolytics completed its domestication from Canada to Nevada and became a U.S. domestic issuer, while retaining a Calgary office and making San Diego its headquarters. The common stock remains listed on the Nasdaq Capital Market under ONCY. The company voluntarily delisted from the Toronto Stock Exchange in August 2025.

06 How pelareorep is designed to work

Pelareorep’s equity thesis rests on more than direct viral killing. The company describes a multi-layer mechanism in which the virus selectively replicates in susceptible cancer cells, triggers inflammatory signaling and helps expand immune cells capable of recognizing viral and tumor antigens. This matters because many gastrointestinal tumors—especially pancreatic ductal adenocarcinoma and most microsatellite-stable colorectal cancers—are poorly responsive to existing immunotherapy.

1. Selective tumor infection and lysis

Pelareorep is designed to exploit signaling abnormalities that can make tumor cells more permissive to reovirus replication. Viral replication can lead to tumor-cell lysis and release antigens into the local environment. RAS-pathway alterations are biologically relevant, but the exact determinants of sensitivity are more complex than a simple “RAS mutation equals response” rule.

2. Innate immune activation

Double-stranded RNA sensing can induce interferon signaling, cytokines and chemokines, activate dendritic cells and change the tumor microenvironment. Translational studies have reported inflammatory changes and tertiary lymphoid structures consistent with a more immune-active tumor state.

3. Adaptive anti-tumor immunity

The company has reported expansion of virus-specific and tumor-reactive T-cell clones after treatment. The strategic goal is to convert immunologically “cold” tumors into tumors that can be recognized more effectively by the immune system and by checkpoint therapy.

Pelareorep has been combined with several chemotherapy backbones and checkpoint inhibitors, including atezolizumab, pembrolizumab, nivolumab and retifanlimab. The platform argument is that pelareorep is not necessarily a stand-alone cytotoxic therapy; it may be most useful as a component that improves the activity and durability of established treatment regimens.

Mechanistic evidence is supportive, not a substitute for clinical proof

Immune activation, T-cell expansion and tertiary lymphoid structure formation make the clinical story more coherent, but biomarkers and translational observations cannot establish that pelareorep improves survival. The decisive evidence must come from controlled clinical trials with credible endpoints, balanced arms and adequate follow-up.

Safety and clinical exposure

The 2025 Form 10-K states that more than 1,200 patients had received pelareorep across the development program. Company disclosures characterize the safety profile as generally manageable, with flu-like events such as fever, chills, fatigue, headache, muscle aches, nausea and gastrointestinal symptoms among the most common treatment-related effects. Safety must still be evaluated within each combination regimen, because chemotherapy and checkpoint inhibitors contribute their own toxicities and a larger registrational program may identify less common events.

07 Oncolytics history: from REOLYSIN to a GI registration strategy

Company formation in Alberta

Oncolytics was incorporated in 1998 and began developing a proprietary reovirus-based cancer therapy that would later be known as REOLYSIN and then pelareorep.

Broad clinical exploration across solid tumors

The company accumulated clinical experience in multiple cancer types and gradually repositioned the asset from a primarily oncolytic-virus concept toward systemic immune activation and combination therapy.

First FDA Fast Track: metastatic breast cancer

The FDA granted Fast Track designation to REOLYSIN/pelareorep in metastatic breast cancer, reflecting the program’s early randomized evidence and unmet need.

Breast cancer SPA and Nasdaq Capital Market listing

Oncolytics reached a Special Protocol Assessment agreement with the FDA regarding a Phase 3 metastatic breast cancer design, and its shares commenced trading on the Nasdaq Capital Market under the symbol ONCY in June 2018. The later development path changed, but these events established the company’s U.S. regulatory and capital-markets footprint.

AWARE-1 builds the immune-priming thesis

The window-of-opportunity AWARE-1 study reported tumor infection, immune activation and achievement of its translational primary endpoint in early-stage HR-positive/HER2-negative breast cancer. The program strengthened the argument that pelareorep can remodel the tumor environment and work with checkpoint blockade.

GOBLET creates pancreatic momentum

Early GOBLET pancreatic cancer cohorts generated unusually high response rates in small patient groups. In December 2022 the FDA granted Fast Track designation for pelareorep with atezolizumab, gemcitabine and nab-paclitaxel in advanced/metastatic pancreatic cancer.

PanCAN funding and anal cancer expansion

Oncolytics received a Pancreatic Cancer Action Network Therapeutic Accelerator Award of up to $5 million for a randomized pancreatic cohort. GOBLET also expanded the clinical story into anal cancer, where the program met internal efficacy criteria.

BRACELET-1 final breast cancer data

The randomized Phase 2 trial reported longer progression-free survival, a higher confirmed response rate and a strong overall-survival signal for pelareorep plus paclitaxel versus paclitaxel alone. The study reinforced the earlier IND.213 signal but did not immediately produce a funded registrational trial.

Leadership transition

After a period under interim leadership, Jared Kelly became CEO in June 2025. His background in biotechnology transactions, followed by the appointment of former Ambrx executive Andrew Aromando as Chief Business Officer, signaled greater emphasis on strategic partnerships and corporate development.

Nasdaq compliance and TSX exit

The company regained compliance with Nasdaq’s minimum bid-price requirement and later voluntarily delisted from the Toronto Stock Exchange, simplifying the public-market structure around Nasdaq.

FDA alignment on a pancreatic Phase 3 design

Oncolytics and the FDA aligned on a potential first-line pancreatic Phase 3 trial using gemcitabine/nab-paclitaxel, pelareorep and an optional checkpoint-inhibitor arm, with overall survival as the primary endpoint.

Anal durability, colorectal Fast Track and strategic narrowing

Updated third-line anal cancer data included two complete responses and two partial responses among 14 evaluable patients. The FDA granted Fast Track in second-line KRAS-mutant MSS colorectal cancer on February 4. On February 24, Oncolytics ended further GOBLET enrollment and prioritized registration-focused colorectal and anal cancer work.

REO 033 launch and U.S. domestication

Oncolytics launched the randomized REO 033 colorectal study, completed its Nevada domestication and entered a new Jefferies ATM facility. An April FDA meeting shifted the planned anal cancer path from the previously discussed single-arm concept toward a randomized controlled pivotal design.

CRC durability, translational data, RAS combinations and IP extension

The company reported a 19.5-month median duration of response in the earlier colorectal dataset, presented mechanistic work at major oncology meetings, announced preliminary preclinical combination activity with RAS-targeted agents, added transaction and operating experience, and obtained a U.S. manufacturing-process patent expected to run into 2044.

REO 033 planning, third GI Fast Track and a Nasdaq compliance notice

On July 13, Oncolytics said half of planned REO 033 sites would be active by the end of July, more than 20 patients had been pre-identified and a Type D FDA meeting was planned for the first half of August; on August 18 the company reported written FDA feedback on the Part B design and said it had forgone that meeting in favour of a later End-of-Phase meeting. On July 20, the FDA granted Fast Track designation in second-line and later anal cancer. Separately, the company received a Nasdaq minimum-bid deficiency letter on July 20 and disclosed it in a Form 8-K signed July 24; the initial cure period runs to January 19, 2027.

08 Pipeline snapshot: active programs versus optionality

A pipeline table can make Oncolytics look broader than its current financing capacity. The more accurate distinction is between programs the company is actively operating, programs with a defined regulatory concept but no confirmed active pivotal trial, and programs whose next major step depends on external funding or a partner.

09 Colorectal cancer: REO 033 is the central value-creation test

Why RAS-mutant MSS colorectal cancer is difficult

Most microsatellite-stable metastatic colorectal cancers do not respond meaningfully to checkpoint-inhibitor monotherapy. RAS mutations further define a biologically important population with limited targeted options outside specific variants and treatment sequences. In the second-line setting after oxaliplatin-based therapy, FOLFIRI plus bevacizumab is a common treatment backbone, but response rates and durability are generally modest.

The signal-generating REO 022 dataset

Oncolytics’ colorectal thesis originated from an earlier study evaluating pelareorep with FOLFIRI and bevacizumab. In the KRAS-mutant MSS second-line subgroup, the company reported:

The magnitude and internal consistency of these endpoints are the strongest part of the colorectal thesis. Response rate, durability, progression-free survival and overall survival all moved in the same direction. Translational work also reported expansion of KRAS-mutant–specific T-cell activity, offering a plausible mechanistic bridge between pelareorep exposure and clinical outcomes.

Why the REO 022 numbers cannot be treated as a registrational result

The key subgroup was small, the analysis was not a prospectively powered randomized comparison for the current claim, and the benchmark comparisons were historical. Patients in small academic cohorts can differ materially from patients in older reference trials. The 33%, 16.6-month, 19.5-month and 27-month figures are therefore best treated as a strong hypothesis that requires controlled confirmation—not as an estimate of what REO 033 will necessarily reproduce.

REO 033 Part A: the active randomized study

REO 033 is an open-label, randomized, multicenter Phase 2 study in patients with RAS-mutated, MSS metastatic colorectal cancer that progressed after one prior oxaliplatin-based regimen. Approximately 60 patients are planned to be randomized 1:1:

• Experimental arm: pelareorep + FOLFIRI + bevacizumab.
• Control arm: FOLFIRI + bevacizumab.
• Primary endpoint: objective response rate by RECIST 1.1.
• Secondary endpoints: progression-free survival, overall survival, safety and tolerability.

ClinicalTrials.gov lists an actual study start of April 30, 2026, estimated enrollment of 60 and recruiting status. On July 13, the company said approximately half of the planned sites were expected to be active by the end of July, the remaining sites by the end of August, and more than 20 potential patients had been pre-identified across centers. The Form 10-Q of August 12, 2026 moved that expectation: approximately half of the planned sites are now expected to be activated during the third quarter of 2026, and no later company update had been published as of September 6, 2026. Pre-identification is not the same as enrollment, but it is a useful operational signal because small oncology trials can be delayed by site activation and eligibility screening.

The proposed registrational Part B

Oncolytics had requested a Type D meeting with the FDA for the first half of August 2026 to discuss adding a larger, registration-directed Part B to REO 033, retaining the core randomized design, increasing enrollment and adding blinded independent central review. On August 18, 2026 the company reported that the FDA had answered in writing: the responses, in the company’s description, represent alignment on the proposed pivotal design, with objective response rate and duration of response as the basis for a potential accelerated approval and progression-free survival for full approval. The FDA suggested an End-of-Phase meeting to reach final agreement on key elements of the registration program, and Oncolytics forwent the scheduled Type D meeting. Part B start-up activities are to begin as soon as positive interim Part A data are available; the decision to launch Part B follows the initial Part A data.

This is an ambitious and potentially efficient strategy, but three points require discipline:

1. The FDA’s written feedback of August 18, 2026 is described by the company as alignment; the final agreement is deferred to an End-of-Phase meeting, and the FDA text is not public.
2. Accelerated approval would still require a compelling surrogate endpoint, adequate safety, manufacturing readiness and an overall benefit-risk package acceptable to the agency.
3. Randomized Part A data could weaken the thesis if the control arm performs better than historical benchmarks or if pelareorep does not create clear separation.

What would constitute a genuinely strong REO 033 update?

The most meaningful early signal would not be a single response. Investors should look for balanced baseline characteristics, an interpretable number of evaluable patients, a higher response rate with pelareorep, early evidence of durable responses, no material safety penalty and FDA acceptance of a feasible Part B. The durability and later PFS/OS curves will matter more than headline response rate alone.

10 Anal cancer: strong unmet need, Fast Track and a changing pivotal design

The treatment context changed in 2025

In May 2025, the FDA approved retifanlimab with carboplatin and paclitaxel as first-line therapy for adults with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal. The agency also approved retifanlimab monotherapy for disease progressing after, or intolerant to, platinum chemotherapy. This created a new first-line standard and changed the logical place for pelareorep.

Oncolytics is now targeting patients whose disease progresses after contemporary first-line treatment that can already include both chemotherapy and checkpoint blockade. The company argues that there is no specifically approved therapy for patients who progress after that current first-line combination. The population is smaller than broad first-line disease, but the unmet need is clearer and may allow a more focused development path.

GOBLET Cohort 4 data

GOBLET Cohort 4 evaluated pelareorep plus atezolizumab in relapsed, unresectable anal cancer. Company disclosures have described:

• Approximately 30% objective response rate in second-line or later patients.
• In a January 2026 third-line analysis, four responses among 14 evaluable patients, including two complete responses and two partial responses.
• Median duration of response near 17 months in the third-line analysis.
• In the broader data package cited for the July Fast Track, median duration of response around 15.5 months and 12-month overall survival of 82%.

Complete responses and long response duration in a heavily pretreated population are clinically interesting. However, the dataset is small, single-arm and compared with historical checkpoint-inhibitor data. The apparent difference could narrow in a randomized trial, especially as standards and patient selection evolve.

From a proposed single-arm study to a randomized pivotal strategy

Before the April 2026 FDA meeting, Oncolytics said it planned to discuss a single-arm registrational approach. After the Type C meeting, the company reported alignment on a randomized controlled pivotal study comparing pelareorep plus a checkpoint inhibitor with a control arm. Management said the same study could potentially support accelerated and full approval at different time points.

This evolution is important. A randomized design raises cost and execution complexity but improves evidentiary credibility. It also suggests the agency expects controlled evidence rather than accepting the small historical-comparison dataset as sufficient on its own.

July 20, 2026 Fast Track designation

The new Fast Track designation confirms that the FDA recognizes the seriousness of the condition and the potential unmet need of the targeted population. It may allow more frequent regulatory interactions, rolling submission of a future Biologics License Application and eligibility for Priority Review if the applicable criteria are met. It does not mean the pivotal protocol is funded, activated or guaranteed to produce an approvable result.

What the anal program adds strategically

The target population is clinically defined, the response durability is notable, complete responses were observed and the unmet need after modern first-line therapy is substantial. A smaller indication may offer a more manageable route to an initial approval than a very large pancreatic Phase 3.

What remains unresolved

Oncolytics has not yet disclosed a finalized pivotal protocol, sample size, trial start date, funding package or checkpoint-inhibitor partner. The program’s scientific promise must therefore be separated from its current operational readiness.

11 Pancreatic cancer: important evidence, but the Phase 3 is partner-dependent

Pancreatic ductal adenocarcinoma was the central Oncolytics narrative before the 2026 strategy pivot. The biological rationale is strong because pancreatic tumors are typically immune-suppressed and poorly responsive to checkpoint therapy. Pelareorep could be valuable if it makes the tumor environment more inflamed and improves immune-cell access or activity.

GOBLET Cohort 1

The first-line GOBLET cohort combined pelareorep, atezolizumab, gemcitabine and nab-paclitaxel. In 13 evaluable patients, early reporting showed a 69% objective response rate, later updated to a confirmed/overall response framework around 62%, with a disease control rate of 85%. The company also reported median progression-free survival around 7.2 months and interim median overall survival around 10.6 months.

These results were encouraging, particularly the response rate, but the cohort was small and lacked a concurrent control. The regimen also contained four agents, making it difficult to isolate the contribution of pelareorep or atezolizumab.

Earlier randomized evidence

The NCI-sponsored randomized study often referred to as NCI-8601 compared carboplatin/paclitaxel-based therapy with or without pelareorep in advanced pancreatic cancer. Conventional median endpoints did not show a dramatic broad advantage, but longer-term survival appeared numerically better in the pelareorep arm. Oncolytics has used pooled and longer-term survival analyses to argue that pelareorep’s benefit may be expressed more clearly in the tail of the curve than in early response or median outcomes.

This is a plausible but still unproven interpretation. Tail-of-curve effects require careful analysis because small numbers at later time points can produce unstable percentages.

GOBLET Cohort 5: separating the checkpoint contribution

GOBLET Cohort 5 randomizes patients to modified FOLFIRINOX plus pelareorep with or without atezolizumab. The design is intended to clarify whether checkpoint inhibition contributes meaningfully to the combination. The cohort is supported by a PanCAN award of up to $5 million. Oncolytics determined in Q1 2026 that enough patients had enrolled for analysis and, in statements made before the second-quarter report, expected a preliminary analysis in the second half of 2026 once survival data mature sufficiently; the Form 10-Q of August 12, 2026 does not repeat that window.

FDA-aligned Phase 3 concept

Following a Type C meeting in late 2025, the company described a potential first-line Phase 3 with:

• Gemcitabine + nab-paclitaxel control.
• Gemcitabine + nab-paclitaxel + pelareorep.
• An optional third arm adding a checkpoint inhibitor.
• Overall survival as the primary endpoint, with PFS and response rate as secondary endpoints.

The key operational fact

The 2025 Form 10-K states that Oncolytics is discussing checkpoint supply and trial funding with potential partners and does not expect to advance the proposed pancreatic registration study on its own until a transaction is completed. The FDA-aligned design is therefore a strategic asset, not an active internally financed Phase 3 program.

A pancreatic partnership would be one of the most material possible corporate catalysts because it could validate the asset, provide non-dilutive funding and restore a major indication to active development. Until a signed agreement exists, however, partnership language should be treated as optionality rather than a forecast.

12 Breast cancer and legacy evidence: clinically relevant, operationally deprioritized

Metastatic breast cancer produced some of pelareorep’s strongest randomized evidence and should not be erased from the history simply because the company is now focused on gastrointestinal tumors. At the same time, the breast program is not a near-term internally funded catalyst.

IND.213

In a randomized Phase 2 study, pelareorep plus paclitaxel did not create a major progression-free survival advantage in the full population, but the company reported a meaningful overall-survival difference, including a larger effect in the HR-positive/HER2-negative subgroup. The divergence between PFS and OS helped establish the idea that immune effects may emerge over time and may not be captured fully by early radiographic endpoints.

AWARE-1

AWARE-1 was a small window-of-opportunity study in early-stage breast cancer designed to examine tumor and immune changes over a short exposure period. It met its translational primary endpoint and reported that pelareorep, alone and with atezolizumab, increased immune activity and could shift tumors toward a more PD-L1-positive phenotype. The study strengthened biological plausibility rather than providing registrational efficacy evidence.

BRACELET-1

BRACELET-1 randomized patients with HR-positive/HER2-negative advanced or metastatic breast cancer to paclitaxel-based arms. In the final 2024 analysis, the company reported:

• Median PFS of 12.1 months with pelareorep + paclitaxel versus 6.4 months with paclitaxel.
• Confirmed ORR of 37.5% versus 13.3%.
• Two-year overall survival of 64% versus 33%.
• Median OS not reached in the pelareorep arm at the protocol-defined end of follow-up; the company provided a conservative estimate of at least 32.1 months versus 18.2 months in the control arm.

These are important randomized signals, but BRACELET-1 was not a pivotal trial and its sample size was limited. Oncolytics has not launched the previously discussed registration-enabling breast study with internal funds. The most realistic near-term value is therefore through a license, partnership or broader strategic transaction.

Why the breast data still matter to the GI thesis

Two randomized breast studies and AWARE-1 reduce the risk that pelareorep’s entire story is based on a single small GI cohort. They provide cross-tumor evidence of immune activity and potential survival benefit. They do not prove efficacy in colorectal or anal cancer, but they strengthen the platform’s biological credibility.

13 Evidence hierarchy: separating proof, signal and company interpretation

Oncolytics has a large volume of clinical material, but not every data point carries the same weight. A disciplined review should rank the evidence rather than count press releases.

What Fast Track means—and what it does not

Potential benefits

• More frequent FDA interactions.
• Possible rolling review of portions of a future application.
• Potential eligibility for Priority Review if criteria are met.
• Ability to resolve development questions earlier.

What it does not provide

• No approval or endorsement of efficacy.
• No guarantee that a pivotal design will be accepted.
• No guarantee of accelerated approval or Priority Review.
• No financing, partner or protection from trial failure.

14 Financial position: near-term milestones funded through equity, not a durable runway

Oncolytics’ financial profile is the principal counterweight to its clinical and regulatory momentum. The company is pre-revenue, has accumulated losses since inception and must fund clinical operations, manufacturing, regulatory work and public-company costs before any approval is possible.

Q2 2026 cash-pressure map

Scale comparison from the Q2 filing. The bars are not a complete cash-flow reconciliation and should not be used as a runway forecast.

Why the cash balance fell despite continued ATM sales

During Q2 2026, Oncolytics sold 7,859,359 shares under the Jefferies agreement for $7.15 million gross and $6.77 million net, at an average price of $0.91. From July 1 through August 10 the company sold another 2,322,984 shares for $1.89 million gross, at an average price of $0.81. Financing replaced part of the cash consumed by operations but not all of it: the balance moved from $5.49 million at March 31 to $4.12 million at June 30, and the average sale price fell across both periods.

Runway should not be presented as a fixed date

The company can alter spending, use the ATM, raise private capital, obtain grants, sign a partnership or defer programs. Because all of these variables can change, a precise “cash lasts until month X” estimate would create false certainty. The most accurate statement is that Oncolytics expects to fund near-term milestones but disclosed that its resources were insufficient for at least twelve months of planned operations as of the Q2 filing.

15 Capital structure and dilution risk

Oncolytics has used equity issuance as its principal financing tool. This does not automatically invalidate the clinical thesis—most small clinical-stage biotechs require repeated financing—but it changes the per-share economics. A successful asset can create value while existing holders still experience substantial ownership dilution if development is financed at low prices.

Common shares outstanding: the dilution slope

Reported common shares outstanding. Percentages show visual scale relative to the August 10, 2026 count, not fully diluted ownership.

From December 31, 2024 to August 10, 2026, the outstanding share count increased by approximately 59.3%. From December 31, 2025 to August 10, 2026, it increased about 18.0%. These calculations measure share-count expansion, not total economic dilution from every potentially issuable security.

ATM capacity

On April 6, 2026, Oncolytics entered an open-market sale agreement with Jefferies allowing sales of up to $75 million of common stock. About $9.04 million of that capacity had been used on a gross basis through August 10, 2026, leaving roughly $66 million. The facility is capacity, not cash already received. The number of shares ultimately issued depends on usage and market prices. A higher share price can reduce the number of shares required to raise a given amount; a lower price has the opposite effect.

Options, warrants and equity awards

At June 30, 2026, the diluted loss-per-share table excluded approximately 34.06 million anti-dilutive securities: 8.20 million warrants, 22.10 million options and 3.76 million RSUs and incentive share awards. They were excluded from accounting dilution because the company reported a loss, but some could become economically relevant if vesting conditions are met or the share price rises above exercise prices.

The 2025 filing also describes transaction-related performance awards, including a potential CEO award based on a percentage of outstanding shares and a Chief Business Officer award tied to an acquisition or exclusive license transaction. Such incentives can align management with a strategic outcome, but they also create potential dilution and are not evidence that a deal is imminent.

What can reduce financing risk

• Strong randomized REO 033 data.
• A funded pancreatic or breast partnership.
• An anal cancer collaboration or checkpoint supply agreement.
• Grant funding or milestone receipts.
• Higher market valuation before equity issuance.

What can amplify dilution

• Slow enrollment or delayed regulatory alignment.
• Weak or ambiguous early data.
• Launching multiple trials without a partner.
• Low share price during ATM use.
• Rising G&A and stock-based compensation.

16 Nasdaq compliance watch: what the July notice actually means

Minimum-bid deficiency under Nasdaq Listing Rule 5550(a)(2)

Oncolytics received the Nasdaq letter on July 20, 2026 after its common stock had closed below $1.00 for 30 consecutive business days. The company disclosed the notice in a Form 8-K signed July 24. The notice did not immediately delist ONCY: the shares continue to trade on the Nasdaq Capital Market, subject to compliance with the exchange’s other requirements.

Management said it intends to monitor the bid price and assess available options. No reverse split was announced in the cited 8-K. A reverse split is therefore a possible future remedy, not a confirmed corporate action as of September 6, 2026.

Why this matters operationally

The cure window overlaps with the expected first randomized REO 033 response update and possible Part B initiation. Positive controlled data could help market valuation, but regulatory progress does not automatically restore listing compliance.

Why this matters per share

The company may need to balance trial funding, ATM usage and listing remedies at the same time. A reverse split would not change enterprise value by itself, but it can alter liquidity, perception and the practical mechanics of future equity issuance.

17 Intellectual property, manufacturing and partnerships

Manufacturing readiness

Biologic and viral therapies can fail commercially even after good clinical data if manufacturing is inconsistent, expensive or insufficiently validated. Oncolytics reported that it had enough drug product for its clinical development program and was preparing drug-substance and fill/finish processes for validation and commercial readiness. In 2025 it completed cGMP production activity and work with a secondary fill/finish supplier.

New U.S. manufacturing patent

In June 2026, the USPTO issued a patent covering the company’s proprietary commercial manufacturing process for pelareorep, which Oncolytics expects to provide protection into 2044. The company has also filed a method-of-use application that, if granted and maintained, is expected to extend protection into 2046. The method-of-use application was pending as of the August 12, 2026 Form 10-Q and should not be treated as an issued patent.

Patent duration does not eliminate competition, validity challenges, design-around risk or regulatory exclusivity questions. It does, however, address a material weakness common to older biotechnology assets: the risk that core composition or process protection expires before commercialization becomes realistic.

PanCAN and strategic collaborations

The Pancreatic Cancer Action Network award provides up to $5 million in eligible support for the randomized GOBLET pancreatic cohort. At June 30, 2026, Oncolytics reported a $1.18 million PanCAN receivable related to eligible spending, recognized $258,000 as a reduction of Q2 research and development expense and $648,000 for the first half, and received no new PanCAN funding during the quarter.

The company also has an exclusive regional licensing arrangement with Adlai Nortye covering territories including China, Hong Kong, Macau, Singapore, South Korea and Taiwan. The agreement can generate development, regulatory and commercial economics, but it has not transformed Oncolytics into a self-funding company.

Partnership strategy

Oncolytics repeatedly states that it is pursuing partnerships to accelerate development. The strongest obvious packages are:

• Pancreatic cancer: a defined FDA-aligned Phase 3 concept requiring funding and potentially checkpoint supply.
• Metastatic breast cancer: two randomized studies plus translational data, but no active registration-enabling trial.
• Anal cancer: Fast Track and a potentially efficient rare-cancer pivotal path, still requiring protocol execution and capital.
• RAS combinations: early preclinical platform extension that could interest targeted-therapy partners if additional data are convincing.

Partnership discipline

Recruiting transaction-experienced executives and directors increases strategic capability, not the probability of a deal to 100%. Only a signed agreement with disclosed economics should be modeled as financing or validation.

18 Management, execution and governance

The leadership profile changed materially in 2025–2026. The current team combines long-standing pelareorep knowledge with newer executives associated with late-stage operations and biotechnology transactions.

Execution positives

• The company moved from a broad program set toward two clearer registration-focused indications.
• REO 033 was launched quickly after colorectal Fast Track.
• FDA interactions in colorectal and anal cancer have been frequent and strategically relevant.
• Manufacturing, patent and operating leadership received attention before pivotal development.

Governance and cost questions

Q2 2026 G&A expense rose to $5.12 million, taking the first half to $9.85 million, including higher public-company and personnel-related costs. Stock-based compensation and consultant shares contributed to the expense and share count. The company must demonstrate that a larger leadership and advisory structure produces faster trial execution, regulatory clarity or partnerships rather than simply increasing overhead.

In July 2026, the board changed the company’s auditor from Ernst & Young to Baker Tilly in connection with corporate restructuring. The 8-K stated that there were no accounting disagreements or reportable events associated with the change. Prior audit reports included going-concern explanatory language, which reflects the financing position rather than an auditor dispute.

Ownership

The 2025 Form 10-K, using information available around March 23, 2026, identified Anson-related entities as beneficial owners of approximately 7.65 million shares, or 6.18%. Current executive officers and directors as a group beneficially owned approximately 4.42 million shares, or 3.67%, including options exercisable within 60 days. Ownership percentages can change rapidly when the company issues shares.

19 Catalyst calendar: dates, windows and what depends on what

One calendar date, several windows. The table separates what the company or a filing has fixed from what depends on data that do not exist yet, at the check of September 6, 2026.

Source: Form 8-K of August 18, 2026 and Form 8-K of July 24, 2026; company releases of July 13 and July 20, 2026; Form 10-Q of August 12, 2026. Windows are the company’s own words and are not dates.

20 Bull, base and bear scenarios

Bull scenario

The FDA accepts an efficient REO 033 Part B framework. Part A shows a clear response advantage without a material safety penalty, and durability begins to resemble the earlier colorectal dataset. The anal pivotal protocol is finalized and funded, potentially with a checkpoint or strategic partner. Pancreatic Cohort 5 supports continued development and helps secure a partnership. Improved market valuation allows capital to be raised with less dilution.

What would prove it: controlled efficacy separation, credible enrollment, signed partnerships and lower financing cost per clinical milestone.

Base scenario

Regulatory interactions remain constructive, but the FDA requires a meaningful randomized sample and longer follow-up. REO 033 enrollment progresses, early data are encouraging but too immature for a decisive conclusion, and the anal trial takes longer to fund and activate. Oncolytics continues using the ATM to bridge milestones. Pancreatic and breast programs remain optional rather than funded.

What it implies: clinical value may increase, but per-share value remains pressured by time and dilution.

Bear scenario

REO 033 fails to reproduce the historical-control advantage, or the control arm performs materially better than assumed. FDA requirements expand trial size and cost. Anal cancer development is delayed, pancreatic data are inconclusive, and no partner emerges. The company raises substantial equity at weak prices, delays programs or pursues strategic alternatives from a position of limited cash.

What would confirm it: weak controlled separation, repeated timeline slippage, accelerated ATM issuance and program reductions.

21 Red flags, falsifiers and monitoring checklist

Clinical and scientific risks

• Small datasets: the most exciting CRC and SCAC figures come from limited patient numbers.
• Historical-control bias: cross-trial comparisons can exaggerate apparent benefit.
• Combination attribution: several regimens include chemotherapy and checkpoint inhibitors, making pelareorep’s individual contribution difficult to isolate without randomized evidence.
• Endpoint uncertainty: response rate may not translate into PFS or OS, while survival-tail hypotheses require long follow-up.
• Cross-indication assumptions: positive breast or pancreatic biology does not guarantee colorectal or anal cancer success.

Regulatory and execution risks

• FDA meeting outcomes can be more demanding than company expectations.
• Accelerated approval standards have become more evidence-intensive and still require confirmatory obligations.
• Small-cap oncology studies can be delayed by contracting, site activation, competing trials and strict eligibility criteria.
• The anal pivotal study has no confirmed public start date, sample size or funding package as of September 6, 2026.
• The pancreatic Phase 3 cannot be treated as active without a partner.

Financial and capital-market risks

• Going-concern disclosure and cash needs create continuous financing sensitivity.
• The $75 million ATM capacity is large relative to the company’s historical cash balance and share base.
• Warrants, options, RSUs and transaction awards add potential future dilution.
• High stock volatility can change the economics of financing quickly.
• Nasdaq compliance: the active minimum-bid cure period creates potential reverse-split and delisting-process risk.
• A partnership may be non-dilutive in cash terms but can transfer substantial territorial or product economics.

Thesis falsifiers

The most direct falsifier would be a well-conducted REO 033 analysis showing no meaningful advantage for pelareorep over the contemporary control arm. Other major falsifiers include inability to agree on a feasible registrational design, repeated failure to activate the anal program, pancreatic randomized data that do not support the platform thesis, or financing that expands the share count faster than clinical value is created.

What to monitor in every update

1. Actual patients enrolled—not only sites opened or patients pre-identified.
2. Evaluable-patient counts and baseline balance between randomized arms.
3. Response durability, PFS and OS—not only ORR.
4. FDA-agreed trial details versus management proposals.
5. Cash, net operating cash use and shares issued after each quarter.
6. Partner economics, rights transferred and cash committed.
7. Manufacturing validation progress before any BLA discussion becomes realistic.

22 Retail sentiment: the narrative around $ONCY

Retail discussion around ONCY tends to divide into two strong narratives. Bullish traders focus on the number of FDA Fast Track designations, durable responses, complete responses in anal cancer, the apparent survival tail across studies, transaction-experienced management and the possibility of a partnership or acquisition. Bearish traders focus on the long corporate history without an approved product, repeated financing, historical-control comparisons, changing lead indications, Nasdaq compliance and the gap between an FDA-aligned concept and a fully funded pivotal program.

On September 6, 2026 the platform’s normalised score for $ONCY read 43, labelled bearish, after a run from 50 on August 4 to 95 on August 19, the day after the FDA feedback release, and back down through the rest of the month; the message-volume score was 49, labelled normal. The bullish and bearish shares of tagged messages came back as 100% and 0%, a degenerate reading that is not quoted. The swing is a useful warning against reading any single day of this series as a verdict on the company.

This sentiment is useful for understanding volatility but not for establishing clinical value. Reddit, Stocktwits and X posts are comments from non-professional traders unless the author is independently verified. They should not be treated as evidence, and social momentum can reverse rapidly around financing disclosures, listing actions or immature data.

Point-in-time Stocktwits data accessed September 6, 2026. Social scores, message classifications and watcher counts can change continuously.

23 Bottom line

Oncolytics reached September 2026 with written FDA feedback on a registrational path in colorectal cancer, the first written FDA feedback on a registrational path for pelareorep in colorectal cancer. Pelareorep now has Fast Track designations across three gastrointestinal indications, the colorectal program is actively randomized, the anal cancer program has a defined post-standard-of-care target and the company has improved its manufacturing-IP position. The earlier breast and pancreatic evidence gives the platform more depth than a typical single-cohort micro-cap oncology story.

The company is also financially fragile. The June 30, 2026 cash balance of $4.12 million was below the quarter’s $8.14 million of operating cash use, the share count has increased sharply, and the new ATM facility gives Oncolytics access to capital by transferring financing risk to current shareholders. The July Nasdaq deficiency notice adds a separate compliance deadline through January 19, 2027. That does not mean the company cannot succeed; it means clinical and regulatory progress must be evaluated on a per-share basis and not only as scientific progress.

The FDA discussion around REO 033 Part B produced written feedback on August 18, 2026; the defining near-term event is now the first controlled colorectal response update from Part A, which the company places by year-end 2026, followed by the End-of-Phase meeting. If randomized evidence confirms a meaningful advantage and the FDA supports an efficient registrational design, the company’s earlier signals may begin to convert into a credible approval path. If the controlled data are weak or the path becomes much larger and more expensive, the historical datasets and Fast Track designations will not protect the equity from clinical and financing pressure.

Research posture

ONCY is a clinical-stage, catalyst-driven biotechnology company with a high-risk financial profile. The science and cross-tumor evidence deserve serious attention, but the underwriting remains preliminary until randomized colorectal data, an executable anal cancer program and a sustainable financing plan are visible. This is an informational assessment, not a recommendation to buy, sell or hold the security.

24 Earlier Merlintrader coverage

These earlier articles preserve the chronology of the story before this Stock Hub. Their financial snapshots and lead-catalyst assumptions should be read in the context of the dates on which they were published.

• Oncolytics Biotech: earlier company and pipeline overview
• Oncolytics Biotech: February 2026 colorectal Fast Track follow-up

The block below is a snapshot of the Stocktwits flow, with its date. These are opinions of retail traders and non-professional investors, not analyst research, and they measure attention and how one-sided positioning has become rather than anything about the business.

25 Follow the next biotech catalysts

Join the Merlintrader Telegram channel for new Stock Hubs, FDA updates, clinical readouts and catalyst-focused market coverage.